Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast CancerAditya Bardia, Leif W. Ellisen, Beverly Moy et al.|Clinical Cancer Research|2024Cited by 43
A TROP2/Claudin Program Mediates Immune Exclusion to Impede Checkpoint Blockade in Breast CancerBogang Wu, Leif W. Ellisen, Steven J. Isakoff et al.|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 5
Supplementary Figure S1 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast CancerAditya Bardia, Leif W. Ellisen, Mark N. Melkonyan et al.|Unknown|2024Cited by 1